Erica Warlick

Erica Warlick, MD, currently serves as Executive Director of Clinical Development at Kura Oncology, Inc., focusing on the Menin Program since March 2024. Previously, Warlick functioned as a Clinical Development Consultant for the Menin Inhibitor Program and founded E. Warlick Consulting LLC in 2024. Warlick's extensive experience includes serving as Medical Director of Clinical Development at Syros Pharmaceuticals from August 2021 to December 2023, where responsibilities included strategic clinical development leadership and overseeing regulatory interactions with the FDA and EMA. Prior to this, Warlick was an Associate Professor of Medicine at the University of Minnesota, engaged in clinical care, research, and medical directorship in Blood and Marrow Transplant, with a background in hematologic malignancy treatment. Warlick completed fellowship training in Hematology and Oncology at Johns Hopkins Hospital following residency in Internal Medicine, and earned a Doctor of Medicine degree from the University of Minnesota Medical School.